−Removed: There are no material changes from the Risk Factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended March 28, 2020.
+Added: There are no material changes from the Risk Factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended April 3, 2021.
Issuer Purchases of Equity Securities
−Removed: In May 2019, our Board of Directors authorized the repurchase of up to $500 million of Haemonetics common shares over the next two years.
−Removed: We had no share repurchases during the nine months ended December 26, 2020.
−Removed: The total remaining authorization for repurchases of our common stock under the share repurchase program was $325 million as of December 26, 2020.
−Removed: We do not expect to make additional share repurchases prior to the expiration of the share repurchase program in May 2021.
+Added: In May 2019, our Board of Directors authorized the repurchase of up to $500 million of Haemonetics common shares over the next two year period ending May 2021.
+Added: During the three months ended July 3, 2021, we did not make any additional repurchases under this program which expired in May 2021.
Defaults Upon Senior Securities
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.